Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugs

Detalhes bibliográficos
Autor(a) principal: Teixeira-Guedes, Catarina
Data de Publicação: 2022
Outros Autores: Brás, Ana Rita, Teixeira, Ricardo G., Valente, Andreia, Preto, Ana
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/1822/80018
Resumo: Colorectal cancer (CRC) is one of the most common malignancies and one of the leading causes of cancer-related death worldwide, urging the need for new and more efficient therapeutic approaches. Ruthenium complexes have emerged as attractive alternatives to traditional platinum-based compounds in the treatment of CRC. This work aims to evaluate anti-CRC properties, as well as to identify the mechanisms of action of ruthenium complexes with the general formula [Ru(η5-C5H4R)(PPh3)(4,4'-R'-2,2'-bipyridine)][CF3SO3], where R = CH3, CHO or CH2OH and R' = H, CH3, CH2OH, or dibiotin ester. The complexes (Ru 1-7) displayed high bioactivity, as shown by low IC50 concentrations against CRC cells, namely, RKO and SW480. Four of the most promising ruthenium complexes (Ru 2, 5-7) were phenotypically characterized and were shown to inhibit cell viability by decreasing cell proliferation, inducing cell cycle arrest, and increasing apoptosis. These findings were in accordance with the inhibition of MEK/ERK and PI3K/AKT signaling pathways. Ruthenium complexes also led to a decrease in cellular clonogenic ability and cell migration, which was associated with the disruption of F-actin cytoskeleton integrity. Here, we demonstrated that ruthenium complexes, especially Ru7, have a high anticancer effect against CRC cells and are promising drugs to be used as a new therapeutical strategy for CRC treatment.
id RCAP_939f6033235cd467322133e6f8eabf6e
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/80018
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugsruthenium complexesanti-colorectal cancer drugsapoptosiscell cycle arrestcytoskeletonCiências Médicas::Medicina BásicaCiências Médicas::Biotecnologia MédicaScience & TechnologyColorectal cancer (CRC) is one of the most common malignancies and one of the leading causes of cancer-related death worldwide, urging the need for new and more efficient therapeutic approaches. Ruthenium complexes have emerged as attractive alternatives to traditional platinum-based compounds in the treatment of CRC. This work aims to evaluate anti-CRC properties, as well as to identify the mechanisms of action of ruthenium complexes with the general formula [Ru(η5-C5H4R)(PPh3)(4,4'-R'-2,2'-bipyridine)][CF3SO3], where R = CH3, CHO or CH2OH and R' = H, CH3, CH2OH, or dibiotin ester. The complexes (Ru 1-7) displayed high bioactivity, as shown by low IC50 concentrations against CRC cells, namely, RKO and SW480. Four of the most promising ruthenium complexes (Ru 2, 5-7) were phenotypically characterized and were shown to inhibit cell viability by decreasing cell proliferation, inducing cell cycle arrest, and increasing apoptosis. These findings were in accordance with the inhibition of MEK/ERK and PI3K/AKT signaling pathways. Ruthenium complexes also led to a decrease in cellular clonogenic ability and cell migration, which was associated with the disruption of F-actin cytoskeleton integrity. Here, we demonstrated that ruthenium complexes, especially Ru7, have a high anticancer effect against CRC cells and are promising drugs to be used as a new therapeutical strategy for CRC treatment.Fundação para a Ciência e Tecnologia (FCT), I.P./MCTES through national funds (PIDDAC)—UIDB/00100/2020, UIDB/04050/2020 and through PTDC/QUI-QIN/28662/2017. A.V. acknowledges the CEECIND 2017 Initiative (CEECCIND/01974/2017). A.R.B. and R.G.T. thank FCT for their Ph.D. Grants (SFRH/BD/139271/2018 and SFRH/BD/135830/2018, respectively)Multidisciplinary Digital Publishing InstituteUniversidade do MinhoTeixeira-Guedes, CatarinaBrás, Ana RitaTeixeira, Ricardo G.Valente, AndreiaPreto, Ana2022-06-172022-06-17T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/1822/80018engTeixeira-Guedes, C.; Brás, A.R.; Teixeira, R.G.; Valente, A.; Preto, A. Ruthenium(II)–Cyclopentadienyl-Derived Complexes as New Emerging Anti-Colorectal Cancer Drugs. Pharmaceutics 2022, 14, 1293. https://doi.org/10.3390/pharmaceutics140612931999-492310.3390/pharmaceutics14061293https://www.mdpi.com/1999-4923/14/6/1293info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:51:23Zoai:repositorium.sdum.uminho.pt:1822/80018Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:50:15.880459Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugs
title Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugs
spellingShingle Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugs
Teixeira-Guedes, Catarina
ruthenium complexes
anti-colorectal cancer drugs
apoptosis
cell cycle arrest
cytoskeleton
Ciências Médicas::Medicina Básica
Ciências Médicas::Biotecnologia Médica
Science & Technology
title_short Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugs
title_full Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugs
title_fullStr Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugs
title_full_unstemmed Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugs
title_sort Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugs
author Teixeira-Guedes, Catarina
author_facet Teixeira-Guedes, Catarina
Brás, Ana Rita
Teixeira, Ricardo G.
Valente, Andreia
Preto, Ana
author_role author
author2 Brás, Ana Rita
Teixeira, Ricardo G.
Valente, Andreia
Preto, Ana
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Teixeira-Guedes, Catarina
Brás, Ana Rita
Teixeira, Ricardo G.
Valente, Andreia
Preto, Ana
dc.subject.por.fl_str_mv ruthenium complexes
anti-colorectal cancer drugs
apoptosis
cell cycle arrest
cytoskeleton
Ciências Médicas::Medicina Básica
Ciências Médicas::Biotecnologia Médica
Science & Technology
topic ruthenium complexes
anti-colorectal cancer drugs
apoptosis
cell cycle arrest
cytoskeleton
Ciências Médicas::Medicina Básica
Ciências Médicas::Biotecnologia Médica
Science & Technology
description Colorectal cancer (CRC) is one of the most common malignancies and one of the leading causes of cancer-related death worldwide, urging the need for new and more efficient therapeutic approaches. Ruthenium complexes have emerged as attractive alternatives to traditional platinum-based compounds in the treatment of CRC. This work aims to evaluate anti-CRC properties, as well as to identify the mechanisms of action of ruthenium complexes with the general formula [Ru(η5-C5H4R)(PPh3)(4,4'-R'-2,2'-bipyridine)][CF3SO3], where R = CH3, CHO or CH2OH and R' = H, CH3, CH2OH, or dibiotin ester. The complexes (Ru 1-7) displayed high bioactivity, as shown by low IC50 concentrations against CRC cells, namely, RKO and SW480. Four of the most promising ruthenium complexes (Ru 2, 5-7) were phenotypically characterized and were shown to inhibit cell viability by decreasing cell proliferation, inducing cell cycle arrest, and increasing apoptosis. These findings were in accordance with the inhibition of MEK/ERK and PI3K/AKT signaling pathways. Ruthenium complexes also led to a decrease in cellular clonogenic ability and cell migration, which was associated with the disruption of F-actin cytoskeleton integrity. Here, we demonstrated that ruthenium complexes, especially Ru7, have a high anticancer effect against CRC cells and are promising drugs to be used as a new therapeutical strategy for CRC treatment.
publishDate 2022
dc.date.none.fl_str_mv 2022-06-17
2022-06-17T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/1822/80018
url https://hdl.handle.net/1822/80018
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Teixeira-Guedes, C.; Brás, A.R.; Teixeira, R.G.; Valente, A.; Preto, A. Ruthenium(II)–Cyclopentadienyl-Derived Complexes as New Emerging Anti-Colorectal Cancer Drugs. Pharmaceutics 2022, 14, 1293. https://doi.org/10.3390/pharmaceutics14061293
1999-4923
10.3390/pharmaceutics14061293
https://www.mdpi.com/1999-4923/14/6/1293
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133086560026624